These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32936260)

  • 1. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).
    Thomas LE; Bonow RO; Pencina MJ
    JAMA Cardiol; 2020 Sep; 5(9):988-990. PubMed ID: 32936260
    [No Abstract]   [Full Text] [Related]  

  • 2. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Guo J; Huang Z; Lin L; Lv J
    J Am Heart Assoc; 2020 Apr; 9(7):e016219. PubMed ID: 32233755
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.
    Kussmaul WG
    Ann Intern Med; 2020 Aug; 173(3):237-238. PubMed ID: 32422077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational data during the COVID-19 pandemic: opportunity with uncertainty.
    Straw S; Witte KK
    Heart; 2020 Oct; 106(19):1461-1462. PubMed ID: 32759292
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.
    Verdecchia P; Angeli F; Reboldi G
    J Hypertens; 2020 Jun; 38(6):1190-1191. PubMed ID: 32371811
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Gersh FL
    Mayo Clin Proc; 2020 Jul; 95(7):1552-1553. PubMed ID: 32622456
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
    Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
    Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
    [No Abstract]   [Full Text] [Related]  

  • 8. Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
    Kansagara D; Mackey K; Vela K
    Ann Intern Med; 2020 Aug; 173(3):W66. PubMed ID: 32584593
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
    Diaz JH
    J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
    Amat-Santos IJ; Santos-Martinez S; López-Otero D; Delgado-Arana JR; San Román JA
    J Am Coll Cardiol; 2020 Oct; 76(17):2042. PubMed ID: 33092743
    [No Abstract]   [Full Text] [Related]  

  • 11. Commentary on "angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic".
    Ferrario CM
    Diabetes Metab Syndr; 2020; 14(5):1401-1402. PubMed ID: 32755842
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to "COVID-19 and ACEI/ARB: Not Associated?".
    Schiffrin EL; Flack JM; Ito S; Muntner P; Webb RC
    Am J Hypertens; 2020 Aug; 33(8):789-790. PubMed ID: 32415836
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 and ACEI/ARB: Not Associated?
    Hajra A; Bandyopadhyay D
    Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
    [No Abstract]   [Full Text] [Related]  

  • 14. ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
    Wang Y; Tse G; Li G; Lip GYH; Liu T
    J Am Coll Cardiol; 2020 Oct; 76(17):2041. PubMed ID: 33092742
    [No Abstract]   [Full Text] [Related]  

  • 15. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial.
    Thomas LE; Li F; Pencina MJ
    JAMA; 2020 Jun; 323(23):2417-2418. PubMed ID: 32369102
    [No Abstract]   [Full Text] [Related]  

  • 16. Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
    Mackey K; Kansagara D; Vela K
    Ann Intern Med; 2020 Sep; 173(5):W87. PubMed ID: 32701362
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.
    Vavougios GD
    Crit Care; 2020 May; 24(1):242. PubMed ID: 32430049
    [No Abstract]   [Full Text] [Related]  

  • 18. Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe COVID-19?
    Aamodt AH; Bjørk MH; Tronvik EA; Buanes EA; Stovner LJ; Atar D
    Tidsskr Nor Laegeforen; 2020 Jun; 140(9):. PubMed ID: 32549022
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19: The heart of the issue.
    Woodward B; Kermali M
    J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
    [No Abstract]   [Full Text] [Related]  

  • 20. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
    Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.